Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive an indication of a configuration for balanced code communication, the configuration indicating parameters of signals of balanced code communications having sequences, within codewords, that balance. The UE may receive, from a network node, a balanced code communication, the receiving comprising decoding a codeword of the balanced code communication and estimating one or more parameters of communicating with the network node based at least in part on the configuration and based at least in part on using a balancing property of the balanced code communication. Numerous other aspects are described.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive a communication comprising data signaling and superimposed pilots, the superimposed pilots being superimposed on the data signaling transmitted via one or more communication resources of the communication. The UE may decode the data signaling from the communication. The UE may measure one or more channels of one or more beams based at least in part on the superimposed pilots. Numerous other aspects are described.

Abstract: Certain aspects of the present disclosure provide method for wireless communications by a user equipment (UE), generally including receiving one or more signals, from a network entity, over a channel, wherein the channel is modeled as a plurality of clusters, determining a plurality of time correlation values for the channel based on the one or more signals, and transmitting a report indicating the plurality of time correlation values for the channel.

Abstract: A device having a biocompatible polymer as a body and regularly spaced radiation seeds and regularly spaced magnetic materials disposed of within the body of the biocompatible polymer, or uniformly distributed liquid radiation and magnetic fluid materials within a polymer slab, hollow thick wall polymer shell, or thin wall polymer balloon, as suitable for surgical placement within a resection cavity for treatment of at-risk tissue in the tumor margin with local hyperthermia in combination with radiation and potentially also with chemotherapy and/or immunotherapy that is slowly released from the biocompatible polymer.

Abstract: A converged device including a first subsystem and a second subsystem, configured to operate in multiple operation modes with varying levels of security. One example provides a method for operating the device. The method includes determining, during a startup sequence of the first subsystem and with a first processor of the first subsystem, a last operation mode for the first subsystem. The method includes determining, responsive to detecting that a SIM is installed in the converged device, a network type for the SIM. The method includes controlling, with the first processor, a first communication interface based on the network type and the last operation mode. The method includes determining, during a startup sequence of the second subsystem and with a second processor of the second subsystem, the last operation mode for the first subsystem and controlling, with the second processor, a second communication interface based on the last operation mode.

Abstract: A converged device including a first subsystem and a second subsystem, configured to operate in multiple operation modes with varying levels of security. One example provides a method for operating the device. The method includes determining, during a startup sequence of the first subsystem and with a first processor of the first subsystem, a last operation mode for the first subsystem. The method includes determining, responsive to detecting that a SIM is installed in the converged device, a network type for the SIM. The method includes controlling, with the first processor, a first communication interface based on the network type and the last operation mode. The method includes determining, during a startup sequence of the second subsystem and with a second processor of the second subsystem, the last operation mode for the first subsystem and controlling, with the second processor, a second communication interface based on the last operation mode.

Abstract: Systems, methods, and related technologies for segmentation management are described. In certain aspects, an entity communicatively coupled to a network is selected and one or more characteristics of the entity may be determined. A segmentation policy may be selected based on the one or more characteristics of the entity and one or more tags to be assigned to the entity based on the segmentation policy may be determined. A zone for the entity based on the one or more tags may be determined and one or more enforcement points associated with the zone for the entity may be determined. One or more enforcement actions may then be assigned to the one or more enforcement points based on the zone associated with the entity.

Abstract: Systems, methods, and related technologies for segmentation management are described. In certain aspects, an entity communicatively coupled to a network is selected and one or more characteristics of the entity may be determined. A segmentation policy may be selected based on the one or more characteristics of the entity and one or more tags to be assigned to the entity based on the segmentation policy may be determined. A zone for the entity based on the one or more tags may be determined and one or more enforcement points associated with the zone for the entity may be determined. One or more enforcement actions may then be assigned to the one or more enforcement points based on the zone associated with the entity.

Abstract: Devices and systems for providing cross-agency communications at an incident are described. An incident manager determines attributes of devices to be used at the incident, negotiating the devices and device attributes with each first responder agency from which devices are to be dispatched to the incident. The manager controls lifecycles of network slices to provide communication services for the incident. The lifecycle is controlled based on communication from each UE indicating arrival to and departure from the incident, as well as the attributes of the UE.

Abstract: The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (DKPs) to modulate various aspects of the immune system such as, for example, inflammation, T-cells and various cytokines.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: A computerized method of facilitating participation in a feature operation executed in a game is provided. The computerized method comprises providing an aggregation platform operatively communicating with at least one remote game server (RGS). The RGS hosts at least one game to be provided to a plurality of players through players' devices. The method further comprises determining, in real time, eligibility of the plurality of players to participate in an operation of a feature shared between the players for a pre-configured event duration, wherein the shared feature operation is executed separately from the game. In response to determining that players are eligible players, facilitating their participation in the execution of the shared feature operation by iteratively selecting one eligible player as possessing a shared feature for a possession iteration having a respective possession duration, and granting an award feature to an eligible player that possesses the shared feature.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: Devices and systems for providing cross-agency communications at an incident are described. An incident manager determines attributes of devices to be used at the incident, negotiating the devices and device attributes with each first responder agency from which devices are to be dispatched to the incident. The manager controls lifecycles of network slices to provide communication services for the incident. The lifecycle is controlled based on communication from each UE indicating arrival to and departure from the incident, as well as the attributes of the UE.

Abstract: The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).